<?xml version="1.0" encoding="UTF-8"?>
<p>Currently, 
 <ext-link ext-link-type="uri" xlink:href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10715" xmlns:xlink="http://www.w3.org/1999/xlink">remdesivir</ext-link>, used against Ebola, and 
 <ext-link ext-link-type="uri" xlink:href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5535" xmlns:xlink="http://www.w3.org/1999/xlink">chloroquine</ext-link>/
 <ext-link ext-link-type="uri" xlink:href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7198" xmlns:xlink="http://www.w3.org/1999/xlink">hydroxychloroquine</ext-link>, used against malaria (Luo et al., 
 <xref rid="bph15207-bib-0058" ref-type="ref">2020</xref>; Yazdany &amp; Kim, 
 <xref rid="bph15207-bib-0085" ref-type="ref">2020</xref>), are being used for COVID‐19 patients. Between the submission and revision of this review article, safety concerns have been raised about the chloroquine/hydroxylchloroquine use in COVID‐19, and the discussion is still open (Paliani &amp; Cardona, 
 <xref rid="bph15207-bib-0065" ref-type="ref">2020</xref>).
</p>
